THE COST-EFFECTIVENESS OF ABATACEPT IN COMBINATION WITH METHOTREXATE FOR THE TREATMENT OF PATIENT WITH ACTIVE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN THE UNITED KINGDOM

被引：0
|
作者：
Lebmeier, M. [1 ]
Pericleous, L. [1 ]
Drost, P. [2 ]
Dequen, P. [3 ]
Ouwens, M. [4 ]
Bergman, G.
Baig, H. [1 ]
机构：
[1] Bristol Myers Squibb Pharmaceut Co, Uxbridge, Middx, England
[2] Bristol Myers Squibb, Braine Ialleud, Belgium
[3] Mapi Values, Bollington, Cheshire, England
[4] Mapi Values, Houten, Netherlands
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)72190-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A309 / A309
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF ABATACEPT FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN CHILE
    Elgart, J. F.
    Gonzalez, L.
    Aiello, E. C.
    VALUE IN HEALTH, 2013, 16 (03) : A223 - A223
  • [2] Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate
    Vera-Llonch, M.
    Massarotti, E.
    Wolfe, F.
    Shadick, N.
    Westhovens, R.
    Sofrygin, O.
    Maclean, R.
    Yuan, Y.
    Oster, G.
    RHEUMATOLOGY, 2008, 47 (04) : 535 - 541
  • [3] Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate in Brazil
    Alves, M. R.
    Carvalho, F., Jr.
    Litalien, G.
    VALUE IN HEALTH, 2008, 11 (03) : A260 - A260
  • [4] Cost effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate
    Vera-Llonch, M.
    Massarotti, E.
    Shadick, N.
    Wolfe, F.
    Westhovens, R.
    Maclean, R.
    Li, T.
    Oster, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 277 - 277
  • [5] Cost-effectiveness of treatment strategies for rheumatoid arthritis patients with inadequate response to methotrexate
    Patel, VD
    Hay, J
    VALUE IN HEALTH, 2004, 7 (03) : 241 - 241
  • [6] COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
    Purcaru, O.
    Taylor, P. C.
    Emery, P.
    Palmer, S.
    VALUE IN HEALTH, 2010, 13 (07) : A310 - A310
  • [7] CANADIAN COST-EFFECTIVENESS ANALYSIS OF ABATACEPT (ORENCIA™) FOR THE MANAGEMENT OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE
    Zou, D.
    Desjardins, O.
    Tsao, N.
    Goeree, R.
    VALUE IN HEALTH, 2010, 13 (03) : A128 - A128
  • [8] Time to treatment response with abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate
    Kremer, J. M.
    Westhovens, R.
    Le Bars, M.
    Lafosse, C.
    Gaillez, C.
    Koncz, T.
    Schmidely, N.
    Dougados, M.
    Schiff, M.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S308 - S308
  • [9] Indirect Treatment Comparison of Abatacept with Methotrexate Versus Other Biologic Agents for Active Rheumatoid Arthritis Despite Methotrexate Therapy in the United Kingdom
    Guyot, Patricia
    Taylor, Peter C.
    Christensen, Robin
    Pericleous, Louisa
    Drost, Pieter
    Eijgelshoven, Indra
    Bergman, Gert
    Lebmeier, Maximilian
    JOURNAL OF RHEUMATOLOGY, 2012, 39 (06) : 1198 - 1206
  • [10] COST-EFFECTIVENESS OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) AFTER THE FAILURE OF A FIRST TNF INHIBITOR IN THE UNITED KINGDOM
    Pericleous, L.
    Lebmeier, M.
    VALUE IN HEALTH, 2011, 14 (07) : A307 - A308
12345